Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada

Canadian Journal of Gastroenterology

Volumn 27, Issue 7, 2013, Pages 397-402

  Fallone, Carlo A ^a   Barkun, Alan N ^a   Szilagyi, Andrew ^b   Herba, Karl M ^a   Sewitch, Maida ^a   Martel, Myriam ^a   Fallone, StefanieS ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Amoxicillin; Clarithromycin; Duration; Helicobacter pylori; Proton pump inhibitor; Triple therapy; Yogurt

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; YOGHURT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CANADA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOLLOW UP; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; STOMACH EROSION; STOMACH ULCER; TASTE DISORDER; TREATMENT DURATION; TREATMENT INDICATION; UREA BREATH TEST;

EID: 84879900780     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/801915     Document Type: Article

References (24)

1. Megraud F, Brassens-Rabbe MP, Denis F, et al. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-3. (Pubitemid 19182896)
2. Fallone CA. Treatment of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2003;49:1-9. (Pubitemid 36505755)
3. Graham DY, Lew GW, Klein PD, et al. Effects of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-8. (Pubitemid 23033112)
4. Lee SK, Lee YC, Chung JB, et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: Treatment strategies based on 10 year follow-up. World J Gastroenterol 2004;10:223-6. (Pubitemid 38195266)
5. .Wong BCY, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187-94. (Pubitemid 38082812)
6. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
7. Chey WD, Wong BCY, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guide on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25. (Pubitemid 47206706)
8. Jones N, Chiba N, Fallone C, et al. Helicobacter pylori in First Nations and recent immigrant populations in Canada. Can J Gastroenterol 2012;26:97-103.
9. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
10. Veldhuyzen van Zanten S, Chiba N, Barkun A, et al. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori. Can J Gastroenterol 2003;17:533-8.
11. Anonymous. The report of the Digestive Health Initiative International Update conference on Helicobacter pylori. Gastroenterology 1997;113(Suppl):S4-8.
12. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: Duration of first line proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62. (Pubitemid 351664506)
13. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: Clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;31:1077-84.
14. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: A critical review. J Clin Gastroenterol 2010;44:313-25.
15. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012;36:534-541.
16. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomized trial. Lancet 2011;378:507-14.
17. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143:55-61.
18. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomized open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
19. Loo VG, Fallone CA, De Souza E, et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997;40:881-3. (Pubitemid 28022155)
20. Glupczynski Y, Megraud F, Lopez-Brea M, Anderson LP. European Multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3. (Pubitemid 34020461)
21. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.
22. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68. (Pubitemid 46046372)
23. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.
24. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: A single center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012;107:922-31.